Using T Cells to Treat B-Cell Cancers

Publisher Website
Google Scholar
Abstract
The Epstein-Barr virus (EBV), a ubiquitous herpesvirus estimated to infect 90 percent of the world's population,1 has been linked to a growing number of diseases, especially in immunocompromised hosts. The first ties between neoplastic disease and EBV were discovered in Burkitt's lymphoma2 and nasopharyngeal carcinoma. The virus has also been found in immunoblastic lymphomas in allograft recipients and persons infected with the human immunodeficiency virus (HIV),3 and in the oral hairy leukoplakia of AIDS. Recently, the EBV genome has been detected in Reed-Sternberg cells in some cases of Hodgkin's disease4 and in KI-1+ lymphoma, various T-cell lymphomas, thymic carcinoma, and . . .